BALPHARMA.BOBALPHARMA.BOBSE
Loading
EBITDA Over TimeStrong
Percentile Rank93
3Y CAGR+9.2%
5Y CAGR+4.3%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+9.2%/yr
vs +7.0%/yr prior
5Y CAGR
+4.3%/yr
Recent acceleration
Acceleration
+2.2pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$318.97M+0.4%
2025$317.63M-0.8%
2024$320.23M+30.7%
2023$245.00M+2.2%
2022$239.71M-7.0%
2021$257.82M+427.5%
2020$48.88M-73.9%
2019$186.92M-1.2%
2018$189.26M+6.0%
2017$178.53M-